GlassScriptPhysician profile
Muhammad A Nayer
NPI 1710090675
$5,181.57
in general payments reported to CMS, 2019-2025
43 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $427 · 2021: $894 · 2022: $705 · 2023: $751 · 2024: $905 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $942.54 | 2019-2025 | Vumerity, Tysabri |
| Pfizer INC. | $762.57 | 2019-2025 | |
| Abbvie INC. | $602.21 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $380.21 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $348.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $303.78 | 2019-2025 | |
| Lundbeck LLC | $159.57 | 2023-2025 | Vyepti |
| Emd Serono, INC. | $140.02 | 2021-2025 | Mavenclad |
| Lilly USA, LLC | $134.31 | 2021-2025 | Amyvid, Kisunla, Zepbound |
| Biohaven Pharmaceuticals, INC. | $132.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $128.76 | 2022 | |
| Celgene Corporation | $107.19 | 2021-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $98.79 | 2019 | |
| Sk Life Science, INC. | $86.85 | 2020-2021 | |
| Genentech USA, INC. | $82.26 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Nayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.